Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin

Vaccine

Volumn 27, Issue 19, 2009, Pages 2616-2624

  Takahashi, Tsuyoshi ^a   Joshi, Suresh G ^b   Al Saleem, Fetweh ^a   Ancharski, Denise ^a   Singh, Ajay ^a   Nasser, Zidoon ^a   Simpson, Lance L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Botulinum toxin; Botulism vaccine; Neutralization

Indexed keywords

BOTULINUM TOXIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN ANTIBODY; IODINE 125; METALLOPROTEINASE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BLOOD LEVEL; BOTULISM; CHOLINERGIC NERVE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FLUORESCENCE MICROSCOPY; HEMIDIAPHRAGM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER; MOUSE; NERVE CELL; NEURO 2A CELL; NEUROMUSCULAR BLOCKING; NONHUMAN; PHRENIC NERVE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; SPLEEN; TRANSCYTOSIS; VACCINATION; WESTERN BLOTTING;

ANIMALS; BACTERIAL VACCINES; BLOOD CHEMICAL ANALYSIS; BOTULINUM ANTITOXIN; BOTULINUM TOXIN TYPE A; FEMALE; LIVER; MICE; PROTEIN BINDING; PROTEIN SUBUNITS; RABBITS; SPLEEN; SURVIVAL ANALYSIS;

EID: 63449094093     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.051     Document Type: Article

References (21)

1. Arnon S.S., Schechter R., and Inglesby T.V. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285 8 (2001) 1059-1070
2. Simpson L.L. Rational development of a vaccine against botulinum toxin. In: Barrett A.D.T., and Stanberry L.R. (Eds). Vaccines for biodefense and emerging and neglected diseases (2009), Elsevier, San Diego pp. 891-917
3. Simpson L.L. Identification of the major steps in botulinum toxin action. Ann Rev Pharmacol Toxicol 44 (2004) 167-193
4. Rossetto O., and Montecucco C. Presynaptic neurotoxins with enzymatic activities. Handb Exp Pharmacol 184 (2008) 129-170
5. Kiyatkin N., Maksymowych A.B., and Simpson L.L. Induction of immune response by oral administration of recombinant botulinum toxin. Infect Immun 65 11 (1997) 4586-4591
6. Smith L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36 11 (1998) 1539-1548
7. Byrne M.P., and Smith L.A. Development of vaccines for prevention of botulism. Biochimie 82 (2000) 955-966
8. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M., Singh A., Gong Y., et al. A trivalent vaccine against botulinum toxin (serotypes A, B, and E) that can be administered by the mucosal route. Infect Immun 75 (2007) 3043-3054
9. Maksymowych A.B., and Simpson L.L. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J Biol Chem 273 34 (1998) 21950-21957
10. Ravichandran E., Gong Y., Al-Saleem F.H., Ancharski D.M., Joshi S.G., and Simpson L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318 3 (2006) 1343-1351
11. Simpson L., Al-Saleem F., Ancharski D., Elias M., Takahaski T., Joshi S., et al. Identification of the mechanisms that account for antibody-induced neutralization of botulinum toxin. Interagency Botulism Research Coordinating Committee Meeting. Philadelphia, PA (2008) [Abstract VA-6]
12. DasGupta B.R., and Sathyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 22 3 (1984) 415-424
13. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 5259 (1970) 680-685
14. Maksymowych A.B., and Simpson L.L. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther 310 2 (2004) 633-641
15. Ahsan C.R., Hajnoczky G., Maksymowych A.B., and Simpson L.L. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J Pharmacol Exp Ther 315 (2005) 1-8
16. Simpson L.L., Maksymowych A.B., and Hao S. The role of zinc binding in the biological activity of botulinum toxin. J Biol Chem 276 29 (2001) 27034-27041
17. Joshi S.G., Francis C.W., Silverman D.J., and Sahni S.K. Nuclear factor kappa B protects against host cell apoptosis during Rickettsia rickettsii infection by inhibiting activation of apical and effector caspases and maintaining mitochondrial integrity. Infect Immunol 71 (2003) 4127-4136
18. Schmidt J.J., and Stafford R.G. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol 69 1 (2003) 297-303
19. Al-Saleem F.H., Ancharski D.M., Ravichandran E., Joshi S.G., Singh A.K., Gong Y., et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 326 3 (2008) 856-863
20. Smith L.A., and Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27 4 (2007) 303-318
21. Jensen M.J., Smith T.J., Ahmed S.A., and Smith L.A. Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41 (2003) 691-701